www.cpexpharm.com
HOME
COMPANY PROFILE
 PERMEATION TECHNOLOGY
TESTIM®
NASULIN
MANAGEMENT
INVESTOR RELATIONS
CONTACT

 
 
The Path to Improved Drug Benefits - Permeation enhancement with CPE-215 is our patented drug delivery technology. CPE-215 enhances the absorption of drugs across a variety of biological membranes including the skin, mouth, nose and eye. The technology can be adapted to products formulated as creams, ointments, gels, solutions, lotions, sprays or patches. CPE-215 also has maintained a record of safety as a direct and indirect food additive and fragrance, and is listed on the FDA’s inactive ingredient list for approved use in drug applications. We believe that key benefits of the patented drug permeation technology of CPEX using CPE-215 may include the following therapeutic and commercial opportunities and advantages:
  • Improved compliance and convenience to patients requiring ongoing injection therapies and the potential for earlier acceptance of prophylactic treatment for patients reluctant to use injections;
  • Application to injectable peptides that could be administered intranasally with CPE-215;
  • Application to therapeutic molecules that are degraded by passage through the liver or would benefit from intra-nasal administration to eliminate first-pass metabolism;
  • Application to a variety of metabolic, neurological and other serious medical conditions;
  • Opportunities for life-cycle extension strategies for existing marketed products;
  • Opportunities for allowing product differentiation based on benefits of administration.
 
The information posted is as of 10/02/2009 and, to our knowledge, was timely and accurate when posted. We are under no obligation to update or remove outdated information other than as required by applicable law or regulation.
 
 
 
FEBRUARY 01, 2010
CPEX PHARMACEUTICALS ANNOUNCES APPOINTMENT OF NEW CHIEF SCIENTIFIC OFFICER
 
JANUARY 08, 2010
CPEX PHARMACEUTICALS REPORTS ON SEC FILING BY ARCADIA CAPITAL ADVISORS
 
DECEMBER 21, 2009
CPEX PHARMACEUTICALS ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 2A CLINICAL TRIAL OF NASULIN™
 

P I P E L I N E
 
P A R T N E R I N G
 
F A C T   S H E E T
 
 
[ HOME | COMPANY PROFILE | MANAGEMENT | INVESTOR RELATIONS | CONTACT ]
 
CPEX PHARMACEUTICALS, INC.
2 HOLLAND WAY
EXETER NH 03833

TEL: 603.658.6100
FAX: 603.658.6101